Rule 12g-4(a)(1) | ☒ | ||||
Rule 12g-4(a)(2) | ☐ | ||||
Rule 12h-3(b)(1)(i) | ☒ | ||||
Rule 12h-3(b)(1)(ii) | ☐ | ||||
Rule 15d-6 | ☐ | ||||
Rule 15d-22(b) | ☐ |
Date: March 21, 2024 | By: | /s/ Adam Stone | |||||||||
Name: Adam Stone | |||||||||||
Title: Interim Chief Executive Officer |
Rule 12g-4(a)(1) | ☒ | ||||
Rule 12g-4(a)(2) | ☐ | ||||
Rule 12h-3(b)(1)(i) | ☒ | ||||
Rule 12h-3(b)(1)(ii) | ☐ | ||||
Rule 15d-6 | ☐ | ||||
Rule 15d-22(b) | ☐ |
Date: March 21, 2024 | By: | /s/ Adam Stone | |||||||||
Name: Adam Stone | |||||||||||
Title: Interim Chief Executive Officer |
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/3/2024 | $5.00 → $3.00 | Buy → Underperform | BofA Securities |
12/22/2023 | $7.00 → $4.00 | Buy → Hold | Jefferies |
15-12G - LianBio (0001831283) (Filer)
EFFECT - LianBio (0001831283) (Filer)
F-6 POS - LianBio (0001831283) (Subject)
BofA Securities downgraded LianBio from Buy to Underperform and set a new price target of $3.00 from $5.00 previously
Jefferies downgraded LianBio from Buy to Hold and set a new price target of $4.00 from $7.00 previously
SC 13D/A - LianBio (0001831283) (Subject)
SC 13D - LianBio (0001831283) (Subject)
SC 13G - LianBio (0001831283) (Subject)
SHANGHAI, China and PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that it has provided notification to The Nasdaq Stock Market, Inc. ("Nasdaq") of its intent to delist the Company's American Depositary Shares ("ADSs"), each representing the right to receive one ordinary share of the Company, from the Nasdaq Global Market. LianBio expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the voluntary delisting of its
SHANGHAI, China and PRINCETON, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the Company's Board of Directors (the "Board") had completed its comprehensive strategic review of the Company and determined to initiate the wind down of its operations, including the sale of remaining pipeline assets, the delisting of its American Depositary Shares ("ADSs"), each representing the right to receive one ordinary share, from the Nasdaq Global Market ("Nasdaq") and deregistration under Section 12(b) of the Securities
• Mavacamten met the primary endpoint for the treatment of Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy • Mavacamten demonstrated a safety profile consistent with previous studies • If approved, mavacamten is expected to be the first cardiac myosin inhibitor approved in China for the treatment of oHCM • LianBio to host a live virtual analyst and investor event to review EXPLORER-CN topline data and the China market opportunity for mavacamten on Monday, May 1 at 8:00 a.m. EDT / 8:00 p.m. CST SHANGHAI, China and PRINCETON, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to pati
SHANGHAI and PRINCETON, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the appointment of Wei Wei Chen to the company's Board of Directors. "I am pleased to welcome Wei Wei Chen to the LianBio board," said Yizhe Wang, Ph.D., Chief Executive Officer of LianBio. "Her deep knowledge of the Chinese market, combined with her ability to manage business growth and transformation, will be extremely beneficial to LianBio as we grow our team and make strides toward advancing our diverse pipeline of potentially transformative medicines for patients
LianBio – ADR (NASDAQ:LIAN) shares are trading higher by some 84% to $0.35 Friday afternoon on continued volatility. The company in late February announced its intent to delist its American Depositary Shares (ADSs) from the Nasdaq Global Market. This decision, made following a strategic review by the Board of Directors, involves winding down operations and deregistering its ordinary shares and ADSs. The company aims to reduce costs associated with regulatory compliance and management time, while returning value to shareholders through asset sales, out-licensing efforts, and dividends. Trading of ADSs post-delisting is expected to shift to privately negotiated sales and potentially an ove
LianBio expects to file a Form 25 with the SEC and Nasdaq relating to the voluntary delisting of its ADSs on or about March 11, 2024. As previously announced, the Company has initiated the wind down of its operations, including the voluntary delisting and deregistration of the company's ordinary shares and ADSs, following the completion of a comprehensive strategic review of the Company by the Board.
Shares of IPG Photonics Corporation (NASDAQ:IPGP) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued soft first-quarter guidance. IPG Photonics posted GAAP earnings of 89 cents per share, versus market estimates of 95 cents per share. The company’s quarterly sales came in at $298.90 million versus expectations of $286.12 million. IPG Photonics shares dipped 11.2% to $92.06 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers Ohmyhome Limited (NASDAQ:OMH) shares climbed 300% to $4.80. BioNexus Gene Lab Corp. (NASDAQ:BGLC) got a boost, surging 270% to $1.52. Digital Brands Group, Inc. (NASD
4 - LianBio (0001831283) (Issuer)
4 - LianBio (0001831283) (Issuer)
4 - LianBio (0001831283) (Issuer)
SHANGHAI, China and PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that it has provided notification to The Nasdaq Stock Market, Inc. ("Nasdaq") of its intent to delist the Company's American Depositary Shares ("ADSs"), each representing the right to receive one ordinary share of the Company, from the Nasdaq Global Market. LianBio expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the voluntary delisting of its
SHANGHAI, China and PRINCETON, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the Company's Board of Directors (the "Board") had completed its comprehensive strategic review of the Company and determined to initiate the wind down of its operations, including the sale of remaining pipeline assets, the delisting of its American Depositary Shares ("ADSs"), each representing the right to receive one ordinary share, from the Nasdaq Global Market ("Nasdaq") and deregistration under Section 12(b) of the Securities
SHANGHAI, China and PRINCETON, N.J., Dec. 20, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that Yi Larson, Chief Financial Officer, has resigned from LianBio to pursue other opportunities, effective December 19, 2023. In connection with her departure, the LianBio Board of Directors has appointed Ehong (Maggie) Gu, current VP, Head of Global Finance, as Interim Chief Financial Officer. "We are grateful to Yi for her many contributions to strategic initiatives at LianBio and wish her continued success in her next role," said Konstantin Poukalov, Executiv